268 related articles for article (PubMed ID: 27140404)
1. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
Mayor M; Zeltsman M; McGee E; Adusumilli PS
Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
[No Abstract] [Full Text] [Related]
2. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
[TBL] [Abstract][Full Text] [Related]
3. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
Maus MV; Haas AR; Beatty GL; Albelda SM; Levine BL; Liu X; Zhao Y; Kalos M; June CH
Cancer Immunol Res; 2013 Jul; 1(1):26-31. PubMed ID: 24777247
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
[TBL] [Abstract][Full Text] [Related]
5. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
6. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
O'Hara MH; Stashwick C; Plesa G; Tanyi JL
Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
O'Hara M; Stashwick C; Haas AR; Tanyi JL
Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
[TBL] [Abstract][Full Text] [Related]
8. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL; Albelda SM; June CH
Cancer Res; 2010 Nov; 70(22):9053-61. PubMed ID: 20926399
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy of solid tumors.
Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
[TBL] [Abstract][Full Text] [Related]
10. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
11. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
[TBL] [Abstract][Full Text] [Related]
12. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
Schuberth PC; Hagedorn C; Jensen SM; Gulati P; van den Broek M; Mischo A; Soltermann A; Jüngel A; Marroquin Belaunzaran O; Stahel R; Renner C; Petrausch U
J Transl Med; 2013 Aug; 11():187. PubMed ID: 23937772
[TBL] [Abstract][Full Text] [Related]
13. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.
Qin L; Lai Y; Zhao R; Wei X; Weng J; Lai P; Li B; Lin S; Wang S; Wu Q; Liang Q; Li Y; Zhang X; Wu Y; Liu P; Yao Y; Pei D; Du X; Li P
J Hematol Oncol; 2017 Mar; 10(1):68. PubMed ID: 28288656
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
16. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
17. CAR T-cell therapy for pancreatic cancer.
DeSelm CJ; Tano ZE; Varghese AM; Adusumilli PS
J Surg Oncol; 2017 Jul; 116(1):63-74. PubMed ID: 28346697
[TBL] [Abstract][Full Text] [Related]
18. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
Tay JC; Zha S; Wang S
Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
Holzinger A; Abken H
Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
[No Abstract] [Full Text] [Related]
20. Engineering CAR-T Cells for Improved Function Against Solid Tumors.
Morgan MA; Schambach A
Front Immunol; 2018; 9():2493. PubMed ID: 30420856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]